How to Sell a Medical Device Patent: Buyers and Timing

Most advice on how to sell a medical device patent is advice on how to sell a patent, with the word medical inserted. Value it, list it, find a buyer, sign the assignment. That sequence is not wrong, it is just missing the variable that decides your price.

In medtech, the regulatory pathway is not context around the asset. It is part of the asset. The predicate you pick to reach the market fastest is the same decision that fixes which companies own the blocking patents, weakens the novelty story an acquirer is buying, and can publish your own invention as prior art against your foreign filings. Sellers discover this in diligence, which is the most expensive place to learn it.

Here is the sale written backwards, from what the buyer's diligence team will actually ask.

The three buyers, and only one of them is browsing

There is no general market for your device patent. There are three specific counterparties.

Strategic device manufacturers with a portfolio gap. They are not shopping. An IP team managing thousands of assets does not read listings, which is why discovery rather than demand is the real bottleneck for a seller. Somebody has to put the asset in front of the right person with an explanation of why it closes a gap they already know they have.

The predicate holder. If your device sits in a product code defined by somebody else's cleared device, that company is the most patent-aware counterparty in your landscape. It has filed on the same technology characteristics your equivalence argument will cite. That cuts both ways: it is the buyer most able to understand you quickly, and the party most likely to already hold something that reads on you.

Licensees who want the rights without the title. Often the right answer, sometimes an expensive detour, and worth deciding deliberately rather than by default. The sell-or-license decision deserves its own terms.

What makes a device patent different

Two things, and both change the number.

The regulatory pathway is priced in

Acquirers treat the route to market as a proxy for how defensible the position is. Recent exit data is blunt about it: among high-value pre-commercial medtech exits, Premarket Approval and De Novo pathways were significantly more prevalent than 510(k) clearances, because a 510(k) relies on substantial equivalence to a predicate, which can inherently undermine arguments for broad patent novelty. The faster regulatory route can be the weaker IP story.

That does not mean holding the patent on a shelf until it looks better. The opposite: a device that has advanced into a regulatory path is generally worth more to an acquirer than a granted patent sitting unused, because acquirers prefer progress over paper, and patent term restoration under Hatch-Waxman can buy back a maximum of five years lost to FDA review. Movement through the regulatory system is evidence. Stillness is not.

Your device is three inventions in one housing

A modern device is hardware, software and often materials at once. Capturing its full value can require apparatus claims, method claims, system claims and software-related claims, and inventors routinely focus on their own area of expertise while other patentable features go undisclosed. The mechanical engineer patents the mechanism and never mentions the control algorithm. A buyer valuing the whole product finds a patent covering a third of it.

Your 510(k) predicate is a pricing decision

This is the section no seller-facing page runs, and it is the one that moves money.

Choosing a predicate tells the FDA your device is equivalent to a specific cleared device in a specific product code. That product code defines the technology space the FDA assesses you against, and it is the same space where the most directly relevant blocking patents are held, so a device that could be cleared against predicates in two different product codes faces two different patent landscapes; predicate substitution is available only before the submission is filed, after which only technology modification remains. The same source makes the point sellers most often get wrong: clearance from the FDA does not mean the device is patent cleared. Two different agencies, two different questions, one of which nobody asked.

Then the disclosure trap. A 510(k) summary becomes a public document through FDA publication or the Freedom of Information Act, and it can be used as prior art against a patent claim's novelty or obviousness; US law gives a one year grace period to file after such a disclosure, but that grace period does not exist in most jurisdictions outside the US, so publication before filing can impair foreign patent rights. A European family lost to a US regulatory filing is a permanent discount on a transatlantic sale, and it is invisible until a buyer's counsel goes looking.

The practical rule: file before the summary publishes, and run the regulatory and IP decisions in the same conversation rather than in sequence. Run a freedom to operate analysis against the product code the clearance actually confirmed, not the broader category you assumed.

Detectability, the question that quietly sets your price

Diligence is predictable. It asks whether the claims read on the product being licensed, whether they can be enforced against competitors, whether there are validity risks the examiner did not consider, and whether prosecution history has created estoppel; when the claims cannot deliver exclusivity, the asset is worth less and the terms reflect the discount through repricing, narrower field-of-use grants, higher indemnity demands, holdbacks, or a walk-away.

Medtech adds its own version of this. A claim practised inside a sealed sterile disposable, inside an implant, or inside firmware nobody can lawfully inspect is a claim you may never be able to show is being infringed. Buyers know this before you do. An undetectable claim is not worthless, it is just worth what a defensive asset is worth, which is a different number from the one in your head.

It is testable in advance, which is why we test it in advance. Every asset we take runs through physics-grade claim reconstruction, detectability analysis and validity probability, benchmarked at 0.76 percent mean absolute percentage error against real-world outcomes. Knowing a claim is hard to detect before outreach costs far less than a buyer discovering it mid-process, because the first is a strategy decision and the second is a repricing.

Sell, license, or the structure that closes

The sharpest number on this topic comes from a worked comparison on a one million dollar target price. A straight asset sale nets roughly 762,000 dollars before state taxes at a 20 percent US federal long-term capital gains rate plus the 3.8 percent Net Investment Income Tax; a hybrid reaching a similar net might pay 250,000 upfront, 250,000 on a milestone such as 510(k) clearance, and a 5 percent royalty; a straight licence runs royalties generally in the 3 to 9 percent range, is taxed as ordinary income, and needs to gross around 1.2 million to reach the same net. Those are illustrative US federal figures from that analysis, not tax advice, and not your situation.

The structural lesson underneath is the important one. Medtech valuation arguments are rarely about market size. They are arguments about who carries the regulatory and reimbursement risk, which is why deals close by allocating that risk rather than pretending to resolve it: milestone payments at points where uncertainty drops, royalty floors and ceilings, and diligence obligations with defined timelines and termination triggers. A common medtech structure runs a 5 percent royalty plus 50,000 dollars at 510(k) clearance plus 100,000 dollars at first commercial sale, because royalty alone undervalues the regulatory work the licensee is financing.

Two clauses to insist on if you license: a minimum annual royalty, and a reversion clause that returns the patent if the licensee stalls. Rights parked by a company with no urgency are the most common way a good device patent quietly expires.

What the number looks like

Benchmarks are a starting point, not an answer. Medical device patent royalties are commonly cited at roughly 3 to 5 percent of net sales, published surveys span 0.1 to 8 percent overall, and the old 25 percent rule was rejected by US courts as damages evidence in 2011. A rate quoted without its royalty base, its exclusivity terms and its duration is not a rate.

Direction matters as much as level, and the direction has not always been kind. A 2017 analysis of 84 healthcare and device licensing transactions recorded between 2010 and 2016 found an average royalty rate of 9.41 percent of net sales across the full period, 10.02 percent in 2010 to 2012, 6.57 percent in 2013 to 2016, and 3.54 percent in 2016. That data is old and the drivers it cites are specific to its moment, so treat it as a caution rather than a forecast: reported medtech rates have moved a long way inside a decade. Nothing here predicts what yours will be. The wider picture on royalty rates across industries and on how a patent is valued is worth reading before you name a price.

The order to run this in

1. File before any 510(k) summary publishes, and before any conference, paper or demonstration.
2. Map every independent claim to the shipping product, element by element, and document the gaps yourself.
3. Check detectability honestly. Decide what you are selling: exclusion, or a defensive position.
4. Run freedom to operate against the confirmed product code.
5. Assemble the package: family listing, clean chain of title, prosecution history, any existing licences.
6. Approach the three buyers deliberately, then close on the closing mechanics of a patent sale.

If the application has not granted, none of this is blocked. The pricing consequences are covered in selling while the application is still pending.

There is also a legitimate answer that is not selling at all. Independent medical inventors rarely have the capital to fight the regulatory process alone, and a suggested price that is simply too low, or a licence needing too many concessions, is a deal worth refusing. No is a position.

How we would run the same sale

We run brokerage as an M&A process rather than a listing, so our economics belong in the open: commission is paid by the seller on completion, with a minimum fee of EUR 5,000 per completed transaction, and no sale means no fee. An optional retainer is credited on close.

The limits in the same breath. EX-IX is not a firm of patent attorneys, filing runs through an independent licensed attorney of record, and a novelty search does not guarantee grant or patentability. We do not give regulatory or tax advice, and no intermediary, us included, can promise you a buyer.

FAQ

Do I need FDA clearance before I can sell a medical device patent? No. Clearance is not a condition of assigning a patent, and plenty of device patents change hands with nothing cleared. It is a pricing input rather than a gate: an application already moving through a regulatory pathway generally reads to an acquirer as progress, while a granted patent with no regulatory movement behind it reads as paper.

Can I sell a medical device patent without a working prototype? Yes, and it is common. Understand what it costs you. Diligence wants the claims mapped onto a real product element by element, and with no embodiment that mapping is hypothetical, so the buyer prices the uncertainty rather than the invention. Bench or clinical data supporting the claimed effect is usually what moves the number, more than the prototype itself.

Does filing a 510(k) hurt my patent position? It can, in two ways. The summary becomes public and can be cited as prior art against your own later filings, and the equivalence statements you make to the FDA are discoverable and can be used to narrow your patent's scope in a later dispute. Neither is a reason to avoid the FDA. Both are reasons to have the patent filed first.

How long does selling a medical device patent take? The transfer mechanics are weeks. The sale is months, because the counterparty has to reconcile your claims with its own product code, its predicate history and its own freedom-to-operate picture before it can price anything. Any timeline that ignores the buyer's internal regulatory review is a timeline for a different industry.

Can I get the patent back if the licensee never launches? Only if you wrote it in. Diligence obligations with defined timelines and termination triggers, a minimum annual royalty, and a reversion clause are the standard protections. Without them, a licensee can hold exclusive rights and do nothing with them until the term runs out, which is a worse outcome than the deal you turned down.